50 results about "Cell Proliferative Activity" patented technology

The invention discloses recombinant IV-type collagen as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the recombinant IV type collagen comprises a plurality of repetitive units, and the repetitive units are shown as SEQ ID NO. 1. The recombinant IV type collagen fragment is derived from human IV type collagen, heterologous amino acid residues are not introduced, and rejection and sensitization risks are avoided; meanwhile, the hydrogel also has good biological activity, including cell proliferation promoting activity and cell adhesion promoting activity, and is good in biocompatibility. In addition, the preparation method of the recombinant IV-type collagen is simple and easy to operate, and the recombinant IV-type collagen with high purity and stability can be obtained through the fermentation and purification method. Therefore, the recombinant IV type collagen disclosed by the invention has a relatively good application prospect.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The present application relates to a kind of purine derivatives as the use of NSD2 and NSD3 inhibitor, the structural formula of the derivative is as shown in formula (I) or formula (II).The compound shows good NSD2, NSD3 inhibitory activity, can effectively reduce the methylation level of H3K36 in cell, and cause the reduction of cell proliferation activity of NSD2, NSD3 high expression tumor cell strain.

The invention discloses application of phloretin in preparation of a medicine for promoting liver cell proliferation, and belongs to the technical field of medicine. A specific cell proliferation tracing system of the hepatocytes is utilized, the proliferation activity of the hepatocytes in an animal body can be continuously recorded, animal experiments find that in the physiological homeostasis maintaining process of a mouse, phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of liver tissue, and it is found through hepatic lobule zoning analysis that phloretin can effectively promote the proliferation activity of the hepatocytes in the animal body without affecting the morphological structure of the liver tissue. The phloretin can effectively promote proliferation of hepatic cells in the first, second and third regions of the hepatic lobule. Therefore, phloretin is a potential medicine for liver regeneration.

The present application relates to the technical field of biology, and particularly relates to a mesenchymal stem cell culture medium and a preparation method and application thereof.The mesenchymal stem cell culture medium comprises a basic culture medium, fetal bovine serum, basic fibroblast growth factor, polymyxin B and deionized water.The present application can simultaneously improve the proliferation activity of mesenchymal stem cells and the secretion performance of HGF by simultaneously adding the basic fibroblast growth factor and the polymyxin B in the basic culture medium; more stem cells can be in the active proliferation and division process by limiting the content of the basic fibroblast growth factor in the mesenchymal stem cell culture medium to 5-50 ng / mL; and the secretion performance of HGF can be improved while the cell proliferation activity is maintained by limiting the content of the polymyxin B in the mesenchymal stem cell culture medium to 50-100 mu g / mL.

The invention discloses a polypeptide, a recombinant XI type humanized collagen formed by the polypeptide and application of the recombinant XI type humanized collagen. Through a large number of screening studies, it is found that a natural human XI type collagen core functional region of recombinant XI type humanized collagen with a triple helix structure can be formed in the in-vitro biosynthesis process. On the basis, the recombinant humanized polypeptide is designed and prepared on the basis of a natural XI type collagen core functional area, and the polypeptide can form a stable triple-helix structure. The recombinant XI type humanized collagen provided by the invention has good biological activities, including promotion of cell proliferation activity, promotion of cell adhesion activity and promotion of extracellular matrix generation or reconstruction, and is suitable for various medical or non-medical applications.

The invention discloses hydrogel loaded with repair-promoting and antioxidant peptides as well as a preparation method and application of the hydrogel, and belongs to the technical field of preparation of medical materials. According to the preparation method, firstly, polypeptide with the amino acid sequence of CEYWVKWCGEKGPAGERG is synthesized, and the polypeptide has antioxidant activity and cell proliferation promoting activity and has good structural stability and enzymatic degradation resistance; and loading the polypeptide into the hyaluronic acid hydrogel to obtain the hyaluronic acid hydrogel. The prepared hydrogel loaded with the repair-promoting and antioxidant peptide has excellent injectable performance and cornea spreadability, can enhance the retention of the polypeptide on the ocular surface, effectively solves the technical problem of high administration frequency of the existing preparation, has good cell and tissue compatibility, and has no adverse reaction in vivo.

This invention relates to the field of biotechnology, specifically disclosing a novel polypeptide, recombinant XIX type humanized collagen, and their applications. This invention provides a novel polypeptide with good cell adhesion activity and the ability to promote cell proliferation. The amino acid sequence of the polypeptide comprises n repeating units; each repeating unit comprises any one of the following (1)-(3) amino acid sequences or their variants: (1) the amino acid sequence shown in SEQ ID NO.1; (2) an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO.1; (3) a variant sequence obtained by mutating one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1; wherein n ≥ 1 and is an integer. The polypeptide of this invention can be used in various fields such as promoting skin barrier repair, wound healing, and epidermal renewal.

A microneedle loaded with at least curcumin, exosomes, and an acellular matrix. Curcumin is incorporated into the exosomes to form functionalized exosomes (Cur@EV), which serve as the primary active ingredient for the repair of hypertrophic scars. Cur@EV has been shown to exhibit a high affinity for hypertrophic scar fibroblasts, while more efficient delivery of curcumin to HSFs has demonstrated enhanced anti-HSF cell proliferation activity and significant anti-fibrosis effects, potentially meeting clinical needs for the repair of hypertrophic scars.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

The invention discloses a medicine for relieving side effects of gastrointestinal tracts caused by nintedanib, a medicine for preventing or treating pulmonary fibrosis and application of stachyose, and belongs to the technical field of medicines. The medicine taking the stachyose as the active ingredient can effectively relieve gastrointestinal tract side effects caused by the nintedanib, for example, intestinal mucosa lesions caused by the nintedanib can be obviously relieved, for example, intestinal mucosa tissue structure abnormity, intestinal cell proliferation activity reduction, intestinal cell apoptosis increase, intestinal tissue inflammatory factor gene expression level up-regulation and the like.

The present invention discloses a methylidene-modified calix[3]carbazole derivative and its preparation method and application, belonging to the field of medical technology. The methylidene-modified calix[3]carbazole derivative of the present invention has a general structural formula as shown in formula (II); in formula (II), R4, R5, and R6 are each independently selected from one of hydroxyl, C1-C3 alkoxy, amino-substituted C1-C5 alkoxy, benzylamino, hydrazine, fatty amine containing O atoms, fatty amine containing N atoms, or ethoxy. The methylidene-modified calix[3]carbazole derivative of the present invention has good activity in inhibiting tumor cell proliferation and has good development prospects in the preparation of anti-tumor drugs.

The invention discloses a method for purifying a recombinant human basic fibroblast growth factor (bFGF). Relates to the technical field of biology. Comprising the following steps: inducing expression of bFGF; soluble protein extraction and primary purification; carrying out primary heparin affinity chromatography purification; the enterokinase of the bFGF trx tag is cut off; and carrying out secondary heparin affinity chromatography purification. The purification process is optimized, so that the product recovery rate is remarkably improved, and the method has the advantage of high large-scale production. The purified bFGF shows remarkable biological activity in a cell proliferation activity experiment; a dose-dependent proliferation promoting effect is shown in a concentration range of 1-10ng / mL; when the concentration is 10ng / mL, the cell proliferation reaches 3.2 + / -0.4 times. Besides, through systematic expression optimization and an innovative purification process, efficient preparation of the high-activity bFGF protein is realized, and a high-quality raw material is provided for the fields of tissue repair and regenerative medicine.

The present invention relates to an edible medium composition having excellent cell proliferation activity. The edible medium composition according to the present invention has the effect of improving cell proliferation activity and inhibiting cellular senescence. In addition, the edible medium of the present invention is literally composed of raw materials that are edible for humans, and thus can be advantageously used as a culture medium for cell-cultured foods. Cells cultured in the edible medium composition of the present invention exhibit higher food safety while also offering cost advantages, compared to cells cultured in conventional media.

The invention relates to the technical field of biology, in particular to desmosome-XVII type collagen fusion protein as well as a preparation method and application thereof. The invention provides a recombinant XVII type collagen fusion protein which comprises at least one XVII type collagen functional domain fragment and at least one functional domain fragment of desmosome core glycoprotein, the recombinant human X VII type collagen fusion protein provided by the invention has better cell adhesion activity and cell proliferation promoting activity. The recombinant human XVII type collagen fusion desmosis protein can significantly improve the adhesion between cells in a cell culture environment, and compared with commercial human XVII type collagen, the recombinant human XVII type collagen fusion desmosis protein can improve the effect by several times or more. In the aspect of promoting cell proliferation, the cell division cycle can be effectively shortened, so that the number of cells is rapidly increased within the same time, and the XVII type collagen is remarkably superior to commercial human XVII type collagen, and has wider application potential in the fields of skin care products, cosmetics, medicines, biomedical materials and the like.

The invention belongs to the technical field of synthetic biology, and particularly relates to a polypeptide, a recombinant XI-type humanized collagen composed of the polypeptide and application of the recombinant XI-type humanized collagen. According to the invention, through a large number of screening researches, a core functional region of a natural human XI type collagen alpha1 (XI) chain and a natural human XI type collagen alpha2 (XI) chain of a recombinant XI type humanized collagen with a triple helix structure can be formed in an in-vitro biosynthesis process. Furthermore, the polypeptide capable of forming the recombinant XI type humanized collagen with the triple-helix structure and the recombinant XI type humanized collagen with the triple-helix structure based on the polypeptide are successfully expressed and prepared for the first time. The recombinant XI type humanized collagen provided by the invention has good biological activity, including promotion of cell proliferation activity and promotion of cell adhesion activity, and is suitable for various medical or non-medical applications.

The present application provides a preparation method for biosynthesis of a human body structural material. A polypeptide has the amino acid sequence of SEQ ID NO. 4, 5 or 6. Recombinant type-VII humanized collagen prepared in the present application has high activity of promoting cell proliferation and does not produce an immune response when applied to a human body, and the preparation method therefor is novel and can obtain the recombinant type-VII humanized collagen on a large scale, and is widely applied in the preparation of human body structural materials.

The invention provides a polypeptide PN-VW22 and application thereof, and belongs to the technical field of polypeptide drugs. The polypeptide PN-VW22 provided by the invention is specifically as follows A1) or A2): A1) an amino acid sequence as shown in SEQ ID NO.1; a2) a fusion protein obtained by connecting a label to the N end or / and C end of A1). The polypeptide has obvious cell proliferation activity and anti-staphylococcus aureus bifunctional activity, and also has a wound repairing effect. The polypeptide is small in molecular weight and stable in structure, can be industrially produced through solid-phase chemical synthesis, can also be industrially applied to preparation of treatment medicines for promoting skin wound repair, and can be used as a candidate polypeptide medicine or a medical beauty product raw material for treating body surface wounds, repairing tissues, burns and skin ulcers, reducing scars and accelerating scar repair.

The present application belongs to the technical field of protein engineering and genetic engineering, and particularly relates to a recombinant collagen XVII and a preparation method and application thereof. Specifically, a brand new recombinant collagen is designed through screening, replacement and splicing, the nucleotide sequence of the recombinant collagen is optimized according to the codon bias of Pichia pastoris, a transmembrane peptide is introduced into the amino terminal of the sequence, a corresponding genetic engineering yeast strain is constructed, and the recombinant collagen is successfully prepared through fermentation. The amino acid sequence of the recombinant collagen has a homology of 100% with the corresponding region of natural human collagen XVII, and there is no immunogenicity risk caused by sequence difference. Meanwhile, the endotoxin content of the protein can be controlled through a purification process, so that no endotoxin residue is ensured. The recombinant collagen prepared by the above technical scheme has more excellent transdermal performance and cell proliferation activity, and has better stability, and therefore has good practical application value.

The invention belongs to the technical field of protein engineering and genetic engineering, and particularly relates to a recombinant XVII type collagen as well as a preparation method and application thereof. Specifically, brand new recombinant collagen is designed by means of screening, replacement, splicing and the like, pichia pastoris codon preference optimization is performed on a nucleotide sequence of the recombinant collagen, cell-penetrating peptide is introduced to an amino terminal of the sequence, a corresponding genetic engineering yeast strain is constructed and obtained, and the recombinant collagen is successfully prepared by fermentation. The homology of the amino acid sequence of the gene and the corresponding region of the natural human source XVII type collagen reaches 100%, and the immunogenicity risk caused by sequence difference does not exist; meanwhile, the endotoxin content of the protein can be controlled through a purification process, and no endotoxin residue is ensured. The recombinant collagen prepared by the technical scheme has more excellent transdermal performance and cell proliferation activity, and also has better stability, so that the recombinant collagen has good practical application value.

The invention provides a tissue phase homogenizing agent and a preparation method and application thereof, and belongs to the technical field of biological tissue engineering, the homogenizing agent is composed of hydrophilic matrixes (glucose, polyglycerol, poloxamer F127 and polyvinyl alcohol), functional additives (mannose, N-acetylcysteine, sodium hyaluronate and polyethylene glycol) and ultrapure water, and the pH value is 7.0 + / -0.2. Hydrophilic groups and water molecules form a hydrogen bond network, a continuous hydration layer is constructed on a phase interface, phase domain fusion, refractive index homogenization and molecular ordering are achieved, the problem of biological tissue phase homogenization is solved, tissue light transmittance can be improved, the swelling ratio can be stabilized, and the hydrogel has cell proliferation promoting activity and is suitable for tissue transplantation operation and bioengineering tissue preservation.

The application discloses a 2-aryl-2,3,4,5-tetrahydro-1,4-epoxybenzazepine compound and application thereof in preparation of an antitumor drug, and a structure of the 2-aryl-2,3,4,5-tetrahydro-1,4-epoxybenzazepine compound is shown as formula I. In vitro tumor cell proliferation inhibition experiments show that the 2-aryl-2,3,4,5-tetrahydro-1,4-epoxybenzazepine compound has good tumor cell proliferation inhibition activity on at least one of human lung cancer cells A549, human colon cancer cells HCT116, human liver cancer cells HepG2 and human breast cancer cells MCF-7, and the 2-aryl-2,3,4,5-tetrahydro-1,4-epoxybenzazepine compound has good antitumor activity and can be applied to preparation of an antitumor drug.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant XIII type humanized collagen and application thereof. According to the invention, a natural human XIII type collagen core functional region is obtained through a large number of screening researches. Based on the core functional area, the recombinant XIII type humanized collagen is successfully expressed and prepared for the first time. The invention relates to the field of biomedical materials, in particular to novel biomedical materials, which have good biological activity, including cell proliferation promoting activity and cell adhesion promoting activity, particularly have good proliferation promoting activity and adhesion promoting activity for skin fibroblasts and keratinocytes, and are suitable for various medical or non-medical applications, such as tissue repair / filling / compatibilization scenarios.

The invention discloses an active polypeptide OA-AL14, application and a preparation for preventing and treating skin photoaging, and belongs to the technical field of biological medicine. The active polypeptide OA-AL14 has the activity of preventing and treating skin photoaging, the amino acid sequence of the active polypeptide OA-AL14 is ALFWPMKKPWPESC, and the molecular weight of the active polypeptide OA-AL14 is 1720.06 Da; researches show that the active polypeptide has obvious ability to remove ABTS < + > free radicals and DPPH free radicals; in a UVB irradiation model test, the active polypeptide OA-AL14 shows the activity of promoting HaCaT cell proliferation and a cell protection effect, and can effectively relieve the oxidative stress reaction of the HaCaT cell induced by UVB and obviously improve the aging of the HaCaT cell induced by UVB; animal experiments further prove that the active polypeptide OA-AL14 can obviously improve UVB-induced skin photoaging, and has important value for development of novel skin photoaging prevention and treatment drugs.

The invention provides a method and system for detecting the malignant degree of endometrial cancer cells, and the method comprises the following steps: judging the influence mechanism of leptin on the malignant degree of cancer cells by detecting parameters such as leptin concentration, JAK2 / STAT3 pathway activation degree, cell proliferation activity, migration and invasion ability and the like; the dynamic association between the leptin concentration change and the activation state of the JAK2 / STAT3 signal channel can be systematically evaluated, the regulation and control effect of the channel on the proliferation, migration and invasion ability of cancer cells is effectively quantified, and a scientific basis is provided for developing treatment schemes and drugs for endometrial cancer.

Provided is a recombinant fibronectin fusion protein comprising a recombinant fibronectin mutant and platelet factor 4, wherein the recombinant fibronectin fusion protein has an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4, and a molecular weight of not more than 90 kDa. The recombinant fibronectin fusion protein exhibits good solubility, has a simple preparation process, and is conveniently purified. The recombinant fibronectin fusion protein comprises a new recombinant fibronectin, and can inhibit inflammation during wound healing, and promote cutaneous wound healing in mice. When platelet factor 4 is fused to the N-terminus of the recombinant fibronectin mutant, cell proliferation activity can be significantly and effectively enhanced.

The present invention relates to the field of natural medicine technology, and specifically to a caged ketone compound extracted from Garcinia macrobracte leaves, as well as a preparation method and use thereof. An insulin resistance model was established by inducing HepG2 cells with palmitic acid, and the hypoglycemic activity of the compound was tested using an in vitro glucose oxidase method. The results showed that the caged ketone compound could significantly increase glucose consumption in HepG2-IR cells and improve the insulin resistance state of HepG2-IR cells to varying degrees. In vitro anti-proliferative activity experiments showed that the caged ketone compound had significant anti-A549 cell proliferation activity. The present invention provides alternative compounds for the development of new hypoglycemic and anti-tumor drugs, which is of great significance to the comprehensive development and utilization of Garcinia macrobracte leaves.

The invention belongs to the technical field of biology, and relates to recombinant humanized collagen as well as a preparation method and application thereof. On the basis of a repeated amino acid region in a natural collagen sequence, diversified design of repetition, combination and deletion of one or more fragments based on the natural sequence is realized, and the recombinant humanized collagen with the amino acid sequence as shown in SEQ ID NO: 1-20 is obtained and is successfully expressed in microorganisms. The material has excellent cell proliferation activity, and has a good application prospect in the fields of medical beauty and biomedical materials.

The application discloses a new application of a wheat germ extract rich in polyamines, and results show that the wheat germ extract rich in polyamines can significantly increase cell migration ability, has the effects of promoting skin repair and healing, and can significantly promote skin fibroblast proliferation, has the effect of promoting cell proliferation activity; can significantly inhibit B16 cell melanin synthesis, has the effect of whitening activity; can delay skin aging, promote skin collagen production, and improve skin hyaluronic acid synthesis. It is shown that the wheat germ extract rich in polyamines prepared in the application can be prepared into health care products, food, cosmetics or medicines for skin repair, skin whitening and delaying skin aging, and a new way is provided for development and utilization of wheat germ.

The application discloses a veratramine compound, a preparation method and application thereof. The application provides a veratramine compound as shown in formula I, which can be used as a series of novel AP-1 inhibitors and used for preparing drugs for corresponding diseases. In preliminary activity research, the compound provided by the application has very strong inhibiting tumor cell proliferation activity, has the potential to be prepared into a novel antitumor drug, and has a good market prospect.